TY - JOUR T1 - Response to: ‘Correspondence on ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’’ by Wang <em>et al</em> JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis SP - e68 LP - e68 DO - 10.1136/annrheumdis-2021-219882 VL - 82 IS - 3 AU - Renaud Felten AU - Jacques-Eric Gottenberg Y1 - 2023/03/01 UR - http://ard.bmj.com/content/82/3/e68.abstract N2 - We read with interest the correspondence related to our article, ‘Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial’, by Wang et al 1 who discuss the disappointing results of recent trials of primary Sjögren syndrome (pSS).To explain recent negative results of tocilizumab and abatacept, apart from the inefficacy of these biologicals in pSS, Wang et al discuss the contribution of the design of the study. First, they discuss the choice of a primary endpoint based on the EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI). As mentioned by the authors, this score captures only the systemic complications of the disease, observed in … ER -